Treatment of hepatitis E virus

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis E virus (HEV) is a significant global pathogen, with genotypes 3 and 4 prevalent in developed countries.
• HEV genotypes 3 and 4 are zoonotic, primarily hosted by pigs, causing acute and chronic infections.
• Chronic HEV infection, particularly in immunosuppressed individuals like transplant recipients, can lead to severe outcomes such as rapidly progressive cirrhosis.

Purpose of the Study:

• To review the current understanding of Hepatitis E virus (HEV) as a global health concern.
• To evaluate the efficacy of ribavirin in treating acute and chronic HEV infections.
• To identify challenges and areas for further research in managing HEV non-responders.

Main Methods:

• Review of existing literature on HEV epidemiology, clinical manifestations, and treatment strategies.
• Analysis of data on the effectiveness of ribavirin monotherapy for chronic HEV.
• Identification of patient groups with treatment failure and exploration of potential reasons.

Main Results:

• Ribavirin is effective for acute HEV in high-risk patients and achieves an approximately 85% sustained virological response (SVR) in chronic HEV cases.
• A minority of chronically infected patients do not achieve SVR with ribavirin monotherapy.
• Treatment for HEV patients who fail to respond to ribavirin remains a clinical challenge, potentially due to viral mutations.

Conclusions:

• Ribavirin is a primary treatment for chronic Hepatitis E virus infection.
• Further research is needed to identify alternative antiviral agents for the subset of patients unresponsive to ribavirin.
• Addressing treatment failures in HEV management is crucial for improving patient outcomes.